Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-04-20

AUTHORS

Naoyuki Uehata, Keita Kouzu, Hironori Tsujimoto, Hidekazu Sugasawa, Kotaro Wakamatsu, Yoji Kishi, Hideki Ueno

ABSTRACT

BackgroundThe prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria.Case presentationA 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5 months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6 mg/kg. The lesion subsequently shrank, but 4 + proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14 months until the PALN was re-enlarged to 13 mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years.ConclusionIn conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits. More... »

PAGES

97

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9

DOI

http://dx.doi.org/10.1186/s40792-021-01185-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1137313504

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33876326


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Uehata", 
        "givenName": "Naoyuki", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kouzu", 
        "givenName": "Keita", 
        "id": "sg:person.01006713465.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006713465.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tsujimoto", 
        "givenName": "Hironori", 
        "id": "sg:person.01022371461.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022371461.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sugasawa", 
        "givenName": "Hidekazu", 
        "id": "sg:person.01357636001.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357636001.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wakamatsu", 
        "givenName": "Kotaro", 
        "id": "sg:person.011621117357.97", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011621117357.97"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kishi", 
        "givenName": "Yoji", 
        "id": "sg:person.0651772025.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651772025.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan", 
          "id": "http://www.grid.ac/institutes/grid.416614.0", 
          "name": [
            "Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ueno", 
        "givenName": "Hideki", 
        "id": "sg:person.01053200431.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053200431.41"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrclinonc.2009.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035657151", 
          "https://doi.org/10.1038/nrclinonc.2009.94"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10120-016-0622-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005167644", 
          "https://doi.org/10.1007/s10120-016-0622-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12882-018-1194-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1111361376", 
          "https://doi.org/10.1186/s12882-018-1194-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-04-20", 
    "datePublishedReg": "2021-04-20", 
    "description": "BackgroundThe prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria.Case presentationA 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5\u00a0months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6\u00a0mg/kg. The lesion subsequently shrank, but 4\u2009+\u2009proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14\u00a0months until the PALN was re-enlarged to 13\u00a0mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years.ConclusionIn conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s40792-021-01185-9", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1052102", 
        "issn": [
          "2198-7793"
        ], 
        "name": "Surgical Case Reports", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "7"
      }
    ], 
    "keywords": [
      "paraaortic lymph nodes", 
      "recurrent gastric cancer", 
      "gastric cancer", 
      "long-term survival", 
      "drug holiday", 
      "PALN metastasis", 
      "disease progression", 
      "positron emission tomography/CT scan", 
      "long-term survival benefit", 
      "prognosis of recurrent", 
      "second-line chemotherapy", 
      "courses of paclitaxel", 
      "unresectable gastric cancer", 
      "advanced gastric cancer", 
      "viable cancer cells", 
      "recurrence 1 year", 
      "SOX therapy", 
      "ramucirumab therapy", 
      "RAM therapy", 
      "PALN recurrence", 
      "distal gastrectomy", 
      "D2 lymphadenectomy", 
      "oxaliplatin therapy", 
      "multidisciplinary treatment", 
      "adverse events", 
      "lymph nodes", 
      "Case presentationA", 
      "conversion surgery", 
      "partial response", 
      "survival benefit", 
      "tumor size", 
      "pathological diagnosis", 
      "ramucirumab", 
      "proteinuria", 
      "CT scan", 
      "monotherapy", 
      "side effects", 
      "ConclusionIn conclusion", 
      "therapy", 
      "cancer", 
      "paclitaxel", 
      "administration", 
      "cancer cells", 
      "patients", 
      "surgery", 
      "metastasis", 
      "progression", 
      "months", 
      "CT", 
      "survival", 
      "course", 
      "lymphadenectomy", 
      "hypertension", 
      "gastrectomy", 
      "chemotherapy", 
      "prognosis", 
      "recurrence", 
      "lesions", 
      "years", 
      "recurrent", 
      "cisplatin", 
      "diagnosis", 
      "dose", 
      "weeks", 
      "women", 
      "scans", 
      "treatment", 
      "withdrawal", 
      "days", 
      "conclusion", 
      "cells", 
      "response", 
      "holidays", 
      "benefits", 
      "events", 
      "effect", 
      "development", 
      "size", 
      "nodes"
    ], 
    "name": "Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer", 
    "pagination": "97", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1137313504"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40792-021-01185-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33876326"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40792-021-01185-9", 
      "https://app.dimensions.ai/details/publication/pub.1137313504"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T21:07", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_875.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s40792-021-01185-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40792-021-01185-9'


 

This table displays all metadata directly associated to this object as RDF triples.

192 TRIPLES      21 PREDICATES      107 URIs      96 LITERALS      7 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40792-021-01185-9 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N6ba1254d219545038a0ace37734116f9
4 schema:citation sg:pub.10.1007/s10120-016-0622-4
5 sg:pub.10.1038/nrclinonc.2009.94
6 sg:pub.10.1186/s12882-018-1194-9
7 schema:datePublished 2021-04-20
8 schema:datePublishedReg 2021-04-20
9 schema:description BackgroundThe prognosis of recurrent and unresectable gastric cancer remains poor despite the development of multidisciplinary treatments. Ramucirumab (RAM) has been proven effective against unresectable or recurrent gastric cancer. However, its administration is often discontinued because of adverse events, including hypertension and proteinuria. We report a patient with recurrent gastric cancer involving the paraaortic lymph node (PALN), who achieved long-term survival after repeated RAM administration following long-term drug holidays due to proteinuria.Case presentationA 79-year-old woman was diagnosed with advanced gastric cancer (cT4aN2) with PALN metastasis. Seven courses of S-1 plus cisplatin (SP) achieved downstaging. A distal gastrectomy with D2 lymphadenectomy was performed as a conversion surgery. The pathological diagnosis was ypT3N2M0. The dissected PALN did not contain viable cancer cells. CT and positron emission tomography/CT scans revealed PALN recurrence 1 year after the surgery. S-1 plus oxaliplatin (SOX) therapy was initiated. The recurrent PALN enlarged after seven courses of SOX therapy. Paclitaxel (PTX) plus ramucirumab (RAM) therapy was initiated as second-line chemotherapy. After three courses of PTX plus RAM therapy, a partial response was observed. PTX was discontinued because of a hematological adverse event 3.5 months after PALN recurrence. Disease progression was not observed after six courses of RAM monotherapy. However, RAM caused proteinuria and was withdrawn for 7 weeks. The recurrent PALN was enlarged on CT, and RAM monotherapy was resumed at a reduced dose of 6 mg/kg. The lesion subsequently shrank, but 4 + proteinuria occurred after three courses of RAM monotherapy. Thus, RAM was discontinued. The patient had chemotherapy-free days for 14 months until the PALN was re-enlarged to 13 mm in size. The three administrations of RAM successfully controlled PALN metastasis and proteinuria for 3 years.ConclusionIn conclusion, even if RAM withdrawal led to disease progression, re-administration of RAM monotherapy while considering its side effects reduced the tumor size and provided long-term survival benefits.
10 schema:genre article
11 schema:isAccessibleForFree true
12 schema:isPartOf N2f3ee3d458474ec3a1790bea5e8d5057
13 N752d4c187a984e73bb18dacf9d84bf98
14 sg:journal.1052102
15 schema:keywords CT
16 CT scan
17 Case presentationA
18 ConclusionIn conclusion
19 D2 lymphadenectomy
20 PALN metastasis
21 PALN recurrence
22 RAM therapy
23 SOX therapy
24 administration
25 advanced gastric cancer
26 adverse events
27 benefits
28 cancer
29 cancer cells
30 cells
31 chemotherapy
32 cisplatin
33 conclusion
34 conversion surgery
35 course
36 courses of paclitaxel
37 days
38 development
39 diagnosis
40 disease progression
41 distal gastrectomy
42 dose
43 drug holiday
44 effect
45 events
46 gastrectomy
47 gastric cancer
48 holidays
49 hypertension
50 lesions
51 long-term survival
52 long-term survival benefit
53 lymph nodes
54 lymphadenectomy
55 metastasis
56 monotherapy
57 months
58 multidisciplinary treatment
59 nodes
60 oxaliplatin therapy
61 paclitaxel
62 paraaortic lymph nodes
63 partial response
64 pathological diagnosis
65 patients
66 positron emission tomography/CT scan
67 prognosis
68 prognosis of recurrent
69 progression
70 proteinuria
71 ramucirumab
72 ramucirumab therapy
73 recurrence
74 recurrence 1 year
75 recurrent
76 recurrent gastric cancer
77 response
78 scans
79 second-line chemotherapy
80 side effects
81 size
82 surgery
83 survival
84 survival benefit
85 therapy
86 treatment
87 tumor size
88 unresectable gastric cancer
89 viable cancer cells
90 weeks
91 withdrawal
92 women
93 years
94 schema:name Long-term survival achieved by repeated administration of ramucirumab after drug holidays due to proteinuria in recurrent gastric cancer
95 schema:pagination 97
96 schema:productId N4521bb77e97f4cb2949d4652575b75a2
97 N54282434bff14e878a400fdcc8da064c
98 N9dcb7898b64642cfa8bc0a27f49277df
99 schema:sameAs https://app.dimensions.ai/details/publication/pub.1137313504
100 https://doi.org/10.1186/s40792-021-01185-9
101 schema:sdDatePublished 2022-11-24T21:07
102 schema:sdLicense https://scigraph.springernature.com/explorer/license/
103 schema:sdPublisher N7998b608aa864ed29a3105a165f09757
104 schema:url https://doi.org/10.1186/s40792-021-01185-9
105 sgo:license sg:explorer/license/
106 sgo:sdDataset articles
107 rdf:type schema:ScholarlyArticle
108 N064d63204d1544d89e67dedad053cf28 rdf:first sg:person.01022371461.19
109 rdf:rest N41e646f34c4b451385e1fe45d111847d
110 N2f3ee3d458474ec3a1790bea5e8d5057 schema:issueNumber 1
111 rdf:type schema:PublicationIssue
112 N41e646f34c4b451385e1fe45d111847d rdf:first sg:person.01357636001.44
113 rdf:rest N4bb29491be1a4adbb761bcf40ad7edd0
114 N4521bb77e97f4cb2949d4652575b75a2 schema:name pubmed_id
115 schema:value 33876326
116 rdf:type schema:PropertyValue
117 N4bb29491be1a4adbb761bcf40ad7edd0 rdf:first sg:person.011621117357.97
118 rdf:rest N643b49954287436484619645e6eb1752
119 N54282434bff14e878a400fdcc8da064c schema:name doi
120 schema:value 10.1186/s40792-021-01185-9
121 rdf:type schema:PropertyValue
122 N643b49954287436484619645e6eb1752 rdf:first sg:person.0651772025.08
123 rdf:rest Ne75b7789f8384af7a2add6160e28a8c0
124 N6ba1254d219545038a0ace37734116f9 rdf:first Ndcea0410d81d41ed814edb53fb9bfcec
125 rdf:rest N83752678249e472393e4c334773211cd
126 N752d4c187a984e73bb18dacf9d84bf98 schema:volumeNumber 7
127 rdf:type schema:PublicationVolume
128 N7998b608aa864ed29a3105a165f09757 schema:name Springer Nature - SN SciGraph project
129 rdf:type schema:Organization
130 N83752678249e472393e4c334773211cd rdf:first sg:person.01006713465.24
131 rdf:rest N064d63204d1544d89e67dedad053cf28
132 N9dcb7898b64642cfa8bc0a27f49277df schema:name dimensions_id
133 schema:value pub.1137313504
134 rdf:type schema:PropertyValue
135 Ndcea0410d81d41ed814edb53fb9bfcec schema:affiliation grid-institutes:grid.416614.0
136 schema:familyName Uehata
137 schema:givenName Naoyuki
138 rdf:type schema:Person
139 Ne75b7789f8384af7a2add6160e28a8c0 rdf:first sg:person.01053200431.41
140 rdf:rest rdf:nil
141 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
142 schema:name Medical and Health Sciences
143 rdf:type schema:DefinedTerm
144 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
145 schema:name Oncology and Carcinogenesis
146 rdf:type schema:DefinedTerm
147 sg:journal.1052102 schema:issn 2198-7793
148 schema:name Surgical Case Reports
149 schema:publisher Springer Nature
150 rdf:type schema:Periodical
151 sg:person.01006713465.24 schema:affiliation grid-institutes:grid.416614.0
152 schema:familyName Kouzu
153 schema:givenName Keita
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01006713465.24
155 rdf:type schema:Person
156 sg:person.01022371461.19 schema:affiliation grid-institutes:grid.416614.0
157 schema:familyName Tsujimoto
158 schema:givenName Hironori
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01022371461.19
160 rdf:type schema:Person
161 sg:person.01053200431.41 schema:affiliation grid-institutes:grid.416614.0
162 schema:familyName Ueno
163 schema:givenName Hideki
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053200431.41
165 rdf:type schema:Person
166 sg:person.011621117357.97 schema:affiliation grid-institutes:grid.416614.0
167 schema:familyName Wakamatsu
168 schema:givenName Kotaro
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011621117357.97
170 rdf:type schema:Person
171 sg:person.01357636001.44 schema:affiliation grid-institutes:grid.416614.0
172 schema:familyName Sugasawa
173 schema:givenName Hidekazu
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357636001.44
175 rdf:type schema:Person
176 sg:person.0651772025.08 schema:affiliation grid-institutes:grid.416614.0
177 schema:familyName Kishi
178 schema:givenName Yoji
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0651772025.08
180 rdf:type schema:Person
181 sg:pub.10.1007/s10120-016-0622-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005167644
182 https://doi.org/10.1007/s10120-016-0622-4
183 rdf:type schema:CreativeWork
184 sg:pub.10.1038/nrclinonc.2009.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035657151
185 https://doi.org/10.1038/nrclinonc.2009.94
186 rdf:type schema:CreativeWork
187 sg:pub.10.1186/s12882-018-1194-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1111361376
188 https://doi.org/10.1186/s12882-018-1194-9
189 rdf:type schema:CreativeWork
190 grid-institutes:grid.416614.0 schema:alternateName Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan
191 schema:name Department of Surgery, National Defense Medical College, 3-2 Namiki, 359-8513, Tokorozawa, Saitama, Japan
192 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...